Pangenomic selects Hong Kong for health AI centre site

Executive Summary

• Pangenomic Health’s wholly owned subsidiary, Mindleap Health, plans to establish a new health AI centre in Hong Kong to support its real-world evidence (RWE) platform for the complementary and alternative medicine (CAM) market.
• The centre, scheduled to launch in the fourth quarter of the current year, will focus on developing, researching, and marketing AI models and health data sets specific to Asia.
• Hong Kong was selected for its diverse patient populations, government support for AI-driven healthcare, status as a medical technology hub, and access to multilingual university researchers in data science and AI.

Key Details

• Entity: Mindleap Health Inc. (wholly owned subsidiary of Pangenomic Health Inc.).
• Action: Establishment of a health AI centre operations hub.
• Location: Hong Kong.
• Timeline: Centre to be set up in the fourth quarter of this year.
• Strategic Rationale:
  • Access to health data sets in Asia.
  • Access to AI models developed by researchers in Asia.
  • Hong Kong’s diverse patient populations.
  • Strong government support for AI-driven health care.
  • Status as a hub for medical technology innovation in the Asia-Pacific region.
  • Access to multilingual university researchers focused on data science, artificial intelligence, and interdisciplinary collaboration.
• Support: Establishment is supported by a strategic advisory firm based in Hong Kong.
• Platform Functionality: The Mindleap RWE platform will collect and analyze health data from traditional and non-traditional sources, including:
  • Clinical research studies from Western and non-Western countries.
  • Long-documented history of human use.
  • Evidence of modern use.
• Goal: To become a trusted source of information about non-pharmaceutical health solutions.

Notable Quotes

• "Mindleap Health is developing a real-world evidence (RWE) platform for the complementary and alternative medicine (CAM) market and key to this platform will be access to health data sets in Asia and AI models developed by researchers in Asia," said Robert Nygren, executive chair of Pangenomic Health and president of its wholly owned subsidiary, Mindleap Health. "With the support of a strategic advisory firm based in Hong Kong, we will set up a health AI centre in the fourth quarter of this year that will include development, research and marketing resources to advance our Mindleap RWE platform for CAM."